Pomdoctor Limited (POM) Fair Value 2026

POM · Pharmaceutical Retailers ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.9 /10

32 fundamental signals · 1 models active

Value Trap Risk

SAFE (0/100)

Quick Summary — As of 2026-08-28, Pomdoctor Limited (POM) trades at $0.95. QOC: 4.9/10. Value Trap Risk: 0/100 (SAFE). 1/13 models active.

Key Facts

Ticker
POM
Price
$0.95
Quality Score
4.9/10
Value Trap Risk
0/100
Models Active
1/13
Last Updated
Strength: PWERM suggests +66.5% upside with 30% confidence
Risk: Below-average Quality Score of 4.9/10 signals weak fundamentals

What Fair Value Does Each Model Give POM?

1 Intrinsic Value Models vs. Current Price ($0.95)

Core Models (Unlocked)
Model Fair Value Upside
Option-Based · Medium Conviction
 $1.58 +66.5%

All Models Active

All 1 models are displayed above.

What Is Pomdoctor Limited (POM) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Pomdoctor Limited is potentially undervalued at its current price of $0.95. Based on our 13-model framework, Pomdoctor Limited's intrinsic value is estimated at a median fair value of $1.58 — representing +66.5% implied upside — with 1 out of 1 active models confirming this thesis.

What Do the Models Say About POM?

1 of 13 models are currently active for POM. All 1 active models suggest the stock trades below fair value. See which stocks rank higher →

How Does POM Rank in Pharmaceutical Retailers?

Among 9 Pharmaceutical Retailers stocks, POM ranks #8 by Quality of Company score. CirclFi's QOC score of 4.9/10 evaluates 32 fundamental signals. A score of 4.9 reflects mixed fundamentals.

Pomdoctor Limited's positioning within the Pharmaceutical Retailers segment means that patent cliff exposure plays an outsized role in fundamental analysis. The sector's unique characteristics — including therapeutic area leadership — shape both the opportunity set and risk profile.

Is POM a Value Trap?

CirclFi's Value Trap algorithm assigns POM a score of 0/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Pomdoctor Limited. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Pomdoctor Limited scores 4.9 out of 10 on our 32-signal quality assessment, a moderate rating that shows mixed signals across our quality framework with notable weaknesses. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every POM valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across POM's 1 active models, average confidence is 30%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Pomdoctor Limited Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Pharmaceutical Retailers Stocks Should You Also Analyze?

8 related Pharmaceutical Retailers stocks with 13-model coverage

BHICBioScience Health Innovations IQOC 6.8PETSPetMed Express, Inc.QOC 6.2HITIHigh Tide Inc.QOC 5.8SHFHScientist Home Future Health LimitedQOC 5.6DHTIDalrada Technology Group Inc.QOC 5.4SCNXScienture Holdings, Inc.QOC 5.2PMHSPolomar Health Services, Inc.QOC 5.2RDGTRidgetech, Inc.QOC 1.8

Read investment analysis: BHIC · PETS · HITI · SHFH · DHTI · SCNX · PMHS · RDGT

Which Other Stocks Have a Similar Quality Score to POM?

7 companies across all industries closest to POM’s Quality of Company score of 4.9/10.

PPTFranklin Premier Income TrustQOC 4.9OSRHOSR Health, Inc.QOC 4.9BCARD. Boral ARC Acquisition I Corp.QOC 4.9LGMKLogicMark, Inc.QOC 4.9TYTri-Continental CorporationQOC 4.9LXEOLexeo Therapeutics, Inc.QOC 4.9NVDANVIDIA CorporationQOC 10.0

Read investment analysis: PPT · OSRH · BCAR · LGMK · TY · LXEO · NVDA

What Else Do Investors Ask About Pomdoctor Limited’s Valuation?

What is Pomdoctor Limited's intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Pomdoctor Limited (POM). The Quality of Company score is 4.9/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is POM overvalued or undervalued right now?

At $0.95, 1 of 1 active models suggest POM may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Pomdoctor Limited's business model in Pharmaceutical Retailers.

What does a Quality of Company score of 4.9 mean for POM?

Pomdoctor Limited's QOC of 4.9/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on POM?

CirclFi analyzes POM with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is POM a value trap in 2026?

Pomdoctor Limited's Value Trap score is 0/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Pomdoctor Limited (POM) a Quality of Company score of 4.9/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/POM/ · Methodology
Primary sources for this POM valuation
  • Financial statements: Pomdoctor Limited 10-K and 10-Q filings on SEC EDGAR (CIK 0001877971) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for POM as of ; valuations recomputed .